Drug Trial Radar · NCT04747197
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
Last checked: Nov 20, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jan 20, 2021
Primary completion
May 11, 2022
Study completion May 11, 2022
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)
Conditions
- Wet Age-related Macular Degeneration
Interventions
EYP-1901Drug
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)Time frame: Week 48
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
EyePoint Investigational Site
Phoenix, Arizona
EyePoint Investigational Site
Beverly Hills, California
EyePoint Investigative Site
Mountain View, California
EyePoint Investigational Site
Oxnard, California
EyePoint Investigational Site
Melbourne, Florida
EyePoint Investigational Site
St. Petersburg, Florida
EyePoint Investigational Site
Springfield, Massachusetts
EyePoint Investigative Site
Asheville, North Carolina
EyePoint Investigational Site
Philadelphia, Pennsylvania
EyePoint Investigational Site
Abilene, Texas
EyePoint Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.